27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Allergan (NYSE: AGN) spiked Friday after it was reported that 13 hedge funds established new positions in the company in the second quarter, while nine added to their stake.
A further six funds boosted their position in the company, while 11 cut their stakes, according to BNK Invest.
Allergan is subject of a hostile takeover bid by Valeant Pharmaceuticals (NYSE: VRX) and activist investor William Ackman's Pershing Square Capital Management LP.
The Securities and Exchange Commission launched a preliminary investigation recently into whether the bid violates insider trading laws, according to reports Thursday.
Ackman issued a statement Friday saying there's "nothing illegal, unethical or improper" in his actions regarding Allergan.
BKN noted that funds operated by Advisory Research and Allstate exited their positions in Allergan during the second quarter, and the total number of Allergan shares held by hedge funds in the period actually fell by more than 19 percent.
Valeant's latest offer for Allergan is $164.16 per share in cash and Valeant stock.
Allergan was down 1.39 percent, trading recently at $157.76 per share.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!